NCT00612066 · ADVERSE EVENTS

Adverse events

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) · Source last updated 2020-08-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Rosiglitazone Rosiglitazone maleate :	0 / 2	1 / 2	Not reported / Not reported

Group identifiers: EG000: Rosiglitazone

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
2
num Events
1
term
edema in limbs

Complete source fields

event Groups

description
Rosiglitazone maleate :
id
EG000
other Num Affected
1
other Num At Risk
2
serious Num Affected
0
serious Num At Risk
2
title
Rosiglitazone

frequency Threshold

other Events

organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
2
num Events
1
term
edema in limbs

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice